Surface charge engineering shields extracellular vesicles from plasma protein corona to enable systemic extrahepatic targeting
Quick Facts
- Publication title: Surface charge engineering shields extracellular vesicles from plasma protein corona to enable systemic extrahepatic targeting
- Journal: Mater Today Bio
- Year: 2026
- DOI: 10.1016/j.mtbio.2026.103471
- PMID/PMCID: 42494417; PMC13392557
Research overview
To disrupt this process, we developed a charge-shielding strategy using positively charged chitosan oligosaccharide (COS) to inhibit PC assembly. Using a biomimetic circulation system, we characterized PC formation and modulation on two clinically relevant EV types: mesenchymal stromal cell-derived EVs (MSC-EVs) and HEK293F-derived EVs (293F-EVs).
Key findings
The plasma protein corona (PC) critically influences the in vivo fate of nanomedicines, yet its composition and impact on extracellular vesicles (EVs) remain poorly defined.
Using a biomimetic circulation system, we characterized PC formation and modulation on two clinically relevant EV types: mesenchymal stromal cell-derived EVs (MSC-EVs) and HEK293F-derived EVs (293F-EVs).
Under dynamic flow, both EV types acquired stable coronas, resulting in increased particle size and decreased surface charge.
Proteomic profiling revealed a shared corona signature enriched in immunoglobulins, complements, and other plasma components.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV proteomics; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Biofluid EV Isolation & Purification, EV Proteomics, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Surface charge engineering shields extracellular vesicles from plasma protein corona to enable systemic extrahepatic targeting Materials today Bio. 2026. DOI: 10.1016/j.mtbio.2026.103471. PMID/PMCID: 42494417; PMC13392557.